Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia . The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. A pharmaceutical composition comprising a purified bacterial mixture of at least two viable bacterial strains selected from the group consisting of Clostridium leptum, Clostridium clostridioforme, Clostridium indolis, Clostridium oroticum, Clostridium scindens, Clostridium sphenoides , and Clostridium symbiosum , wherein the bacterial strains are isolated from a human, wherein the pharmaceutical composition is formulated for delivery to the intestine, and wherein the pharmaceutical composition does not include Bacteroides.
2. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition further does not include Lactobacillus or Bifidobacterium.
3. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is in a capsule.
4. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is formulated for delivery to the colon.
5. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is formulated for oral administration.
6. The pharmaceutical composition of claim 1 , wherein said at least two viable bacterial strains are in a spore form.
7. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises Clostridium scindens.
8. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition comprises between about 10 7 and about 10 9 viable microbes or between about 10 9 and about 10 11 viable microbes.
9. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is effective for treating inflammatory bowel disease.
10. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is effective for treating Crohn's disease.
11. The pharmaceutical composition of claim 1 , wherein said pharmaceutical composition is effective for treating ulcerative colitis.
12. A pharmaceutical composition comprising a purified bacterial mixture of at least two viable bacterial strains selected from the group consisting of Clostridium indolis, Clostridium scindens, Clostridium symbiosum , and Blautia producta , wherein said pharmaceutical composition is formulated for delivery to the intestine, and wherein said pharmaceutical composition does not include Bacteroides.
13. The pharmaceutical composition of claim 12 , wherein said purified bacterial mixture comprises all four bacterial strains of Clostridium indolis, Clostridium scindens, Clostridium symbiosum , and Blautia producta.
14. The pharmaceutical composition of claim 13 , wherein said pharmaceutical composition is in a capsule.
15. The pharmaceutical composition of claim 13 , wherein said pharmaceutical composition is in an enteric coated capsule.
16. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition comprises Clostridium scindens.
17. The pharmaceutical composition of claim 12 , wherein said at least two viable bacterial strains are in a spore form.
18. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition does not include Lactobacillus or Bifidobacterium.
19. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition comprises between about 10 7 and about 10 9 viable microbes or between about 10 9 and about 10 11 viable microbes.
20. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition is effective for treating inflammatory bowel disease.
21. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition is effective for treating Crohn's disease.
22. The pharmaceutical composition of claim 12 , wherein said pharmaceutical composition is effective for treating ulcerative colitis.